CLINICAL, CYTOGENETIC AND MOLECULAR CHARACTERIZATION OF BRAZILIAN COHORT PATIENTS WITH PRIMERY MYELOFIBROSIS AND MYELOFIBROSIS POST-POLYCYTTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA

Autor: Tavares, RS, Clementino, NCD, Conchon, MRM, Pagnano, KBB, Santana, SA, Nascimento, ACKVD, Funke, VAM, Centrone, RT, Seguro, FS, Bortolini, JAP, Silveira, DA, Bendit, I

Publikováno v: In Hematology, Transfusion and Cell Therapy October 2021 43 Supplement 1:S128-S128

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

Autor: Mahon FX; University of Bordeaux, Bordeaux, France (F.M.)., Boquimpani C; Hemocentro do Rio de Janeiro, HEMORIO, Rio de Janeiro, Brazil (C.B.)., Kim DW; The Catholic University of Korea, Seoul, South Korea (D.K.)., Benyamini N; Rambam Health Care Campus, Haifa, Israel (N.B.)., Clementino NCD; Hospital Das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil (N.C.C.)., Shuvaev V; Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia (V.S.)., Ailawadhi S; Mayo Clinic, Jacksonville, Florida (S.A.)., Lipton JH; University of Toronto, Toronto, Ontario, Canada (J.H.L.)., Turkina AG; National Research Center for Hematology, Moscow, Russia (A.G.T.)., De Paz R; University Hospital La Paz, Madrid, Spain (R.D.)., Moiraghi B; Hospital General De Agudos J. M. Ramos Mejia, Buenos Aires, Argentina (B.M.)., Nicolini FE; Centre Hospitalier Lyon Sud, Pierre-Bénite, France (F.E.N.)., Dengler J; Onkologische Praxis Heilbronn, Heilbronn, Germany (J.D.)., Sacha T; Jagiellonian University Hospital, Kraków, Poland (T.S.)., Takahashi N; Akita University Hospital, Akita, Japan (N.T.)., Fellague-Chebra R; Novartis Pharma SAS, Rueil-Malmaison, France (R.F.)., Acharya S; Novartis Healthcare Pvt Ltd, Hyderabad, India (S.A.)., Wong S; Novartis Oncology Precision Medicine, Cambridge, Massachusetts (S.W.)., Jin Y; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Y.J.)., Hughes TP; University of Adelaide, Adelaide, South Australia, Australia (T.P.H.).

Publikováno v: Annals of internal medicine [Ann Intern Med] 2018 Apr 03; Vol. 168 (7), pp. 461-470. Date of Electronic Publication: 2018 Feb 20.

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Autor: Hughes TP; Division of Haematology, SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia., Leber B; Clinical Pathology, McMaster University, Hamilton, Ontario, Canada., Cervantes F; Department of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain., Spector N; Departamento de Clínica Médica/FM, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Pasquini R; Division of Hematology and Medical Oncology, Federal University of Paraná, Curitiba, Brazil., Clementino NCD; Hospital Das Clinicas da UFMG, Belo Horizonte, Brazil., Schwarer AP; Department of Hematology, Alfred Hospital, Melbourne, Victoria, Australia., Dorlhiac-Llacer PE; Department of Hematology, Hospital das Clinicas FMUSP, São Paulo, Brazil., Mahon FX; Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U1035, Université Victor Ségalen, Bordeaux, France., Rea D; Unité de Thérapie Cellulaire et Clinique Transfusionnelle, Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, Paris, France., Guerci-Bresler A; Department of Hematology, Brabois Hospital, Vandoeuvre-lès-Nancy, Vandoeuvre, France., Kamel-Reid S; Clinical Laboratory Genetics, Genome Diagnostics, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada., Bendit I; Hematology Unit, Faculty of Medicine, University of São Paulo, São Paulo, Brazil., Acharya S; Novartis Healthcare Pvt Ltd, Hyderabad, India., Glynos T; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Dalal D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Branford S; Leukaemia Unit, Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide, Adelaide, South Australia, Australia., Lipton JH; Blood and Marrow Transplant Service, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Publikováno v: Leukemia [Leukemia] 2017 Nov; Vol. 31 (11), pp. 2529-2531. Date of Electronic Publication: 2017 Aug 03.

The prevalence of anemia in people with chronic kidney disease after hematopoietic stem cell transplantation.

Autor: Kępska-Dzilińska, Małgorzata¹, Karakulska-Prystupiuk, Ewa², Kaszyńska, Aleksandra¹, Basak, Grzegorz W.², Małyszko, Jolanta¹ jolanta.malyszko@wum.edu.pl

Publikováno v: Renal Failure. Dec2023, Vol. 45 Issue 2, p1-5. 5p.

Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a systematic review and meta-analysis.

Autor: Zheng, Zhenxiang, Tang, Hao, Zhang, Xinxia, Zheng, Liling, Yin, Zhao, Zhou, Jie, Zhu, Yangmin

Publikováno v: Discover Oncology; 10/23/2024, Vol. 15 Issue 1, p1-18, 18p